公开(公告)号：WO1997002246A1

公开(公告)日：1997-01-23

申请号：PCT/US1995008460

申请日：1995-07-06

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC. ,  LAMBERT, Carol ,  MEASE, Ronnie, C. ,  MCAFEE, John, G.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC.

IPC: C07D213/20

CPC classification number: G01N33/5094 ,  A61K51/0455 ,  A61K51/1203 ,  A61K2123/00 ,  C07B59/002 ,  C07D213/38

Abstract: A compound is provided of formula (I) wherein n is 4-16, Det is an organic group comprising a radioisotope or capable of chelating a radioisotope, and Z is one equivalent of a biologically acceptable anion, which compounds are useful to radiolabel cellular membranes, as of hematopoietic cells.

Abstract translation: 提供式（I）的化合物，其中n为4-16，Det为包含放射性同位素或能够螯合放射性同位素的有机基团，Z 1为1当量的生物可接受的阴离子，该化合物可用于 放射性标记细胞膜，如造血细胞。

公开(公告)号：WO1996040178A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009627

申请日：1996-06-07

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  SELAWRY, Helena, P.

IPC: A61K35/48

CPC classification number: C12N5/0683 ,  A61K35/12 ,  A61K35/39 ,  A61K35/48 ,  A61K35/55 ,  A61K38/13 ,  A61K38/28 ,  A61K48/00 ,  A61K2035/122 ,  A61K2035/126 ,  A61K2035/128 ,  C12N5/0676 ,  C12N5/0677 ,  C12N2502/246 ,  C12N2510/00 ,  C12N2510/04 ,  A61K2300/00

Abstract: The present invention describes a method of treating a disease that results from a deficiency of a biological factor which comprises administering to a mammal Sertoli cells and cells that produce the biological factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site and providing cell stimulatory factors in a mammal for transplants is further described by the present invention. A method of co-localizing islet cells with Sertoli cells and the use of the co-localized product for treating diabetes mellitus is further provided. The present invention further describes a method of creating systemic tolerance to foreign antigens. A method of enhancing the viability, maturation, proliferation of functional capacity of cells in tissue culture is further provided. A pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is also provided.

Abstract translation: 本发明描述了一种治疗由生物因子缺乏引起的疾病的方法，其包括对产生生物因子的哺乳动物Sertoli细胞和细胞施用。 特别地，本发明描述了通过移植胰腺细胞胰岛胰岛细胞与Sertoli细胞结合来产生免疫特异性位点来治疗糖尿病的方法。 通过本发明进一步描述了在哺乳动物中产生免疫特异性位点并为移植物提供细胞刺激因子的方法。 进一步提供了与Sertoli细胞共定位胰岛细胞并使用共定位产物治疗糖尿病的方法。 本发明还描述了一种对外源抗原产生系统耐受性的方法。 进一步提供增强组织培养细胞功能能力的活力，成熟，增殖的方法。 还提供了包含产生生物因子的Sertoli细胞和细胞的药物组合物。

公开(公告)号：WO1996039377A1

公开(公告)日：1996-12-12

申请号：PCT/US1996008626

申请日：1996-06-04

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  PIRKLE, William, H. ,  WELCH, Christopher, J. ,  LAMM, Bo, Robert

IPC: C07C275/30

CPC classification number: C07C51/487 ,  C07C275/30

Abstract: The invention relates to a chiral selector useful in separating underivatized enantiomers of nonsteroidal anti-inflammatory agents, particularly naproxen and other arylacetic acid compounds, and relates to a process for achieving such separation utilizing the chiral selector, which is also useful in achieving the enantiomeric separation of amines, alcohol derivatives, epoxides and sulfoxides. The invention is also directed to an apparatus which comprises the chiral selectors.

Abstract translation: 本发明涉及可用于分离非甾体抗炎剂，特别是萘普生和其它芳基乙酸化合物的未衍生化对映异构体的手性选择剂，涉及使用手性选择剂实现这种分离的方法，其也可用于实现对映体分离 的胺，醇衍生物，环氧化物和亚砜。 本发明还涉及一种包括手性选择器的装置。

公开(公告)号：WO1996035642A1

公开(公告)日：1996-11-14

申请号：PCT/US1996006470

申请日：1996-05-07

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  PEYTON, Gary, Rodger

IPC: C02F01/70

CPC classification number: C02F1/72 ,  C02F1/02 ,  C02F1/30 ,  C02F1/32 ,  C02F1/34 ,  C02F1/36 ,  C02F1/70 ,  C02F1/722 ,  C02F1/725 ,  C02F1/78 ,  C02F9/00 ,  C02F2101/003 ,  C02F2101/363 ,  C02F2101/38 ,  Y10S210/908 ,  Y10S210/909

Abstract: A process is provided for treating aqueous streams contaminated with electron affinic contaminants. Accordingly, these contaminants are removed by producing a reactive intermediate that is generated in-situ and then reacting the reactive intermediate thus produced with the electron affinic contaminant. The reactive intermediate is produced in the aqueous stream by maintaining low levels of oxygen in the stream and by providing a reducing radical precursor, such as an alcohol, to the aqueous stream.

Abstract translation: 提供了一种处理受电子亲和污染物污染的含水物流的方法。 因此，通过产生原位生成的反应性中间体，然后使由此产生的反应性中间体与电子亲和性污染物反应来除去这些污染物。 反应性中间体在水流中通过保持流中的低水平并通过向水流中提供还原性自由基前体，例如醇而产生。

公开(公告)号：WO1996000291A1

公开(公告)日：1996-01-04

申请号：PCT/US1995007820

申请日：1995-06-20

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  BANDURSKI, Robert, Stanley ,  SZERSZEN, Jedrzej, Bogumil ,  SZCZYGLOWSKI, Krzysztof

IPC: C12N15/54

CPC classification number: C12N9/1051 ,  C12N15/8294

Abstract: Plant growth and plant growth habit can be controlled without the application of exogenous plant hormones or hormone mimetics using the nucleic acid sequences and methods provided. UDP-Glucose: Indol-3-ylacetyl-glucosyl transferase (IAGlu Transferase) amino acid sequence and nucleic acid coding sequences for this enzyme, specifically exemplified for Zea mays, are provided. Nucleic acid constructs directing the expression of IAGlu Transferase and the expression of antisense RNA specific therefor allows the control of growth habit and plant size in transgenic plants containing such nucleic acid constructs.

Abstract translation: 可以使用提供的核酸序列和方法来控制植物生长和植物生长习性，而不需要使用外源植物激素或激素模拟物。 提供UDP-葡萄糖：吲哚-3-基乙酰 - 葡糖基转移酶（IAGlu转移酶）氨基酸序列和该酶的核酸编码序列，其具体示例为Zea mays。 指导IAGlu转移酶表达的核酸构建体和其特异性的反义RNA的表达允许控制含有此类核酸构建体的转基因植物中的生长习性和植物大小。

公开(公告)号：WO1995032298A3

公开(公告)日：1995-11-30

申请号：PCT/US1995006176

申请日：1995-05-16

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  PATHAK, Vinay, K. ,  HU, Wei-Shau

IPC: C12N15/86

公开(公告)号：WO1995026416A1

公开(公告)日：1995-10-05

申请号：PCT/US1995003611

申请日：1995-03-22

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  PIUNNO, Paul, A., E. ,  HUDSON, Robert, H., E. ,  KRULL, Ulrich, J.

IPC: C12Q01/68

CPC classification number: G01N21/648 ,  C12Q1/6825 ,  G01N21/6428 ,  G01N21/7703 ,  G01N2021/7786

Abstract: A biosensor for direct analysis of nucleic acid hybridization by use of an optical fiber is disclosed. Single-stranded nucleic acid probes are immobilized onto the surface of optical fibers and undergo hybridization with complementary single-stranded nucleic acids introduced into the local environment of the sensor. Hybridization events are detected by the use of fluorescent compounds which intercalate into double-stranded nucleic acids. The invention finds uses in detection and screening of genetic disorders, viruses, and pathogenic microorganisms. Biotechnology applications include monitoring of cell cultures and gene expression. The invention includes biosensors systems in which fluorescent molecules are tethered to immobilized single-stranded nucleic acid. The preferred method for immobilization of single-stranded nucleic acids is by in situ solid phase nucleic acid synthesis.

Abstract translation: 公开了通过使用光纤直接分析核酸杂交的生物传感器。 将单链核酸探针固定在光纤表面上，并与引入传感器局部环境的互补单链核酸进行杂交。 通过使用插入双链核酸的荧光化合物来检测杂交事件。 本发明用于遗传病症，病毒和致病微生物的检测和筛选。 生物技术应用包括监测细胞培养和基因表达。 本发明包括生物传感器系统，其中荧光分子束缚于固定的单链核酸。 用于固定单链核酸的优选方法是通过原位固相核酸合成。

公开(公告)号：WO1995025749A2

公开(公告)日：1995-09-28

申请号：PCT/US1995003660

申请日：1995-03-22

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  TSO, Patrick

IPC: C07K14/775

CPC classification number: C07K14/775 ,  A23L33/18 ,  A61K38/00

Abstract: Peptides corresponding to specific portions of the apolipoprotein A-IV (apo A-IV) are provided. Most of the peptides correspond to the amino terminal region of apo A-IV. In addition, those peptides corresponding to the amino terminal portion of apo A-IV substantially correspond to a fundamental repeat unit of twenty two amino acids comprising: D Y F T Q L S N N A K E A V E Q L Q K T D V as well as homologs and analogs thereof. The peptides have eating suppressant properties when administered centrally or peripherally. the peptides may be used in compositions and methods for suppressing the appetite and controlling food intake.

Abstract translation: 提供了与载脂蛋白A-IV（载脂蛋白A-IV）的特定部分相对应的肽。 大多数肽对应于载脂蛋白A-IV的氨基末端区域。 此外，对应于载脂蛋白A-IV的氨基末端部分的那些肽基本上对应于二十二个氨基酸的基本重复单元，其包含：D Y F T Q L S N N A K E A V E Q L Q K T D V以及其同系物和类似物。 当中心或外周施用时，肽具有抑制抑制性质。 肽可以用于抑制食欲和控制食物摄入的组合物和方法中。

公开(公告)号：WO1995012817A1

公开(公告)日：1995-05-11

申请号：PCT/CA1993000452

申请日：1993-11-05

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  NESHEIM, Michael, E. ,  MANUEL, Reginald, P.

IPC: G01N33/86

CPC classification number: C12Q1/56 ,  G01N33/573 ,  G01N33/86 ,  G01N2333/8128 ,  G01N2333/96444 ,  G01N2333/974 ,  G01N2400/40 ,  Y10S435/968

Abstract: A method for assaying body fluid samples containing heparin and a diagnostic kit are described. Since the reactions go to completion, timing of the assay is not required. The sample is mixed with a heparin-dependent protease inhibitor and either a heparin-independent irreversible inhibitor or a protease substrate. The coagulation enzyme (protease) is then added in a limiting quantity and it either distributes between the heparin-dependent inhibitor and the heparin-independent irreversible inhibitor, or the heparin-dependent inhibitor and the protease substrate. The distribution pattern of complex formation of the protease with the two inhibitors or the level of product of the protease-catalyzed hydrolysis of the substrate are used as measures of the heparin activity. The irreversible inhibitor is a peptidyl chloromethyl ketone and the substrate is a synthetic chromogenic or fluorogenic compound that produces a readily measured signal.

Abstract translation: 描述了用于测定含有肝素的体液样品和诊断试剂盒的方法。 由于反应完成，不需要测定的时间。 将样品与肝素依赖性蛋白酶抑制剂和不依赖肝素的不可逆抑制剂或蛋白酶底物混合。 然后以限制的量加入凝血酶（蛋白酶），并且其分配在肝素依赖性抑制剂和不依赖肝素的不可逆抑制剂或肝素依赖性抑制剂和蛋白酶底物之间。 使用两种抑制剂的蛋白酶复合物形成的分布模式或蛋白酶催化的底物水解产物的水平被用作肝素活性的量度。 不可逆抑制剂是肽基氯甲基酮，底物是产生容易测量信号的合成显色或荧光化合物。

公开(公告)号：WO1995009559A2

公开(公告)日：1995-04-13

申请号：PCT/US1994010982

申请日：1994-09-28

Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.

Inventor： RESEARCH CORPORATION TECHNOLOGIES, INC. ,  HENDRICKS, James, B. ,  MEHTA, Jawahar, L.

IPC: A61B00/00

CPC classification number: G01N33/56972 ,  G01N33/56966

Abstract: A method and means for detection of an acute myocardial infarction (AMI) in a patient are provided. The method involves sampling of a patient's peripheral blood, quantifying the level of monocyte platelet conjugates (MP-C) and determining whether a significant increase in monocyte platelet conjugates is present. Quantification can be achieved by direct counting of monocyte platelet conjugates on a slide or a microscope, by instrumentation measuring apparent monocyte cell volume increases, flow cytometry, or cell counter employing electrical resistance pulse sizing or light scattering. Diagnostic test kits for detecting an AMI are also provided.

Abstract translation: 提供了一种用于检测患者急性心肌梗死（AMI）的方法和装置。 该方法涉及对患者外周血的取样，定量单核细胞血小板共轭物（MP-C）的水平并确定是否存在单核细胞血小板共轭物的显着增加。 可以通过在载玻片或显微镜上直接计数单核细胞血小板共轭物，通过测量表观单核细胞体积增加，流式细胞术或使用电阻脉冲施加或光散射的细胞计数器来进行定量。 还提供了用于检测AMI的诊断试剂盒。